Published in Cancer Res on June 29, 2010
Molecular mechanisms and clinical applications of angiogenesis. Nature (2011) 13.36
Initial steps of metastasis: cell invasion and endothelial transmigration. Mutat Res (2011) 1.67
PlGF: a multitasking cytokine with disease-restricted activity. Cold Spring Harb Perspect Med (2012) 1.32
PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity. Clin Cancer Res (2016) 0.91
TIMP-2 targets tumor-associated myeloid suppressor cells with effects in cancer immune dysfunction and angiogenesis. J Immunother (2012) 0.86
Primary Tumor-Secreted Lymphangiogenic Factors Induce Pre-Metastatic Lymphvascular Niche Formation at Sentinel Lymph Nodes in Oral Squamous Cell Carcinoma. PLoS One (2015) 0.77
The pre-metastatic niche: is metastasis random? Bonekey Rep (2012) 0.76
Molecular and functional imaging of invasion and metastasis: windows into the metastatic cascade. Cancer Biomark (2010) 0.76
Exosomal Annexin A2 Promotes Angiogenesis and Breast Cancer Metastasis. Mol Cancer Res (2016) 0.75
Cancer and the metastatic substrate. Ecancermedicalscience (2016) 0.75
Exosomal tetraspanins mediate cancer metastasis by altering host microenvironment. Oncotarget (2017) 0.75
The biology of VEGF and its receptors. Nat Med (2003) 32.13
The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer (2003) 22.78
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature (2005) 15.57
Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 14.55
Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer (2009) 14.17
Paradoxical roles of the immune system during cancer development. Nat Rev Cancer (2006) 10.57
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 6.76
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature (2009) 6.67
Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell (2009) 6.66
MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell (2002) 4.93
Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci U S A (1998) 4.82
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer (2008) 3.46
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med (2003) 3.17
Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell (2010) 2.64
SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion. Nat Genet (2007) 2.39
Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc Natl Acad Sci U S A (2002) 2.27
Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood (2005) 1.98
Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol Cancer Ther (2008) 1.83
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res (2009) 1.64
VEGFR1-activity-independent metastasis formation. Nature (2009) 1.47
VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation. PLoS One (2009) 1.23
Neuropilin is a mediator of angiogenesis. Cancer Metastasis Rev (2000) 1.21
A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. Oncologist (2010) 1.11
Molecular mechanisms and clinical applications of angiogenesis. Nature (2011) 13.36
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell (2004) 8.78
Photodynamic therapy for cancer. Nat Rev Cancer (2003) 8.00
Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res (2004) 5.65
Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 5.64
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov (2011) 5.59
Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med (2003) 5.50
Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat Med (2009) 5.41
Lymphatic metastasis in the absence of functional intratumor lymphatics. Science (2002) 5.32
Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol (2002) 5.04
Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol (2012) 4.84
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol (2009) 4.54
Tissue engineering: creation of long-lasting blood vessels. Nature (2004) 4.50
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med (2009) 3.85
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol (2005) 3.83
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol (2013) 3.81
Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res (2007) 3.64
Pathology: cancer cells compress intratumour vessels. Nature (2004) 3.60
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol (2010) 3.43
Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature (2002) 3.40
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol (2009) 3.39
Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci U S A (2011) 3.34
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov (2011) 3.34
Diffusion and convection in collagen gels: implications for transport in the tumor interstitium. Biophys J (2002) 3.25
Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat Med (2005) 3.19
Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. Blood (2008) 3.13
The role of nitric oxide in tumour progression. Nat Rev Cancer (2006) 3.08
Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol (2009) 3.02
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res (2009) 3.00
Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res (2013) 2.98
Response criteria for glioma. Nat Clin Pract Oncol (2008) 2.69
Engineering vascularized tissue. Nat Biotechnol (2005) 2.69
Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem (2007) 2.67
Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A (2012) 2.66
Endothelial cells derived from human embryonic stem cells form durable blood vessels in vivo. Nat Biotechnol (2007) 2.65
Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell (2013) 2.64
Differential in vivo potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels. Blood (2007) 2.64
Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci U S A (2010) 2.62
A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc (2007) 2.59
Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol (2006) 2.58
Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation (2010) 2.53
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A (2012) 2.50
Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res (2006) 2.42
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res (2011) 2.40
CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res (2011) 2.39
Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res (2006) 2.35
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun (2013) 2.31
Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res (2002) 2.29
Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci U S A (2011) 2.27
The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature (2004) 2.22
Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng (2011) 2.17
The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol (2011) 2.16
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A (2013) 2.14
Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis. Circ Res (2003) 2.12
p53 controls radiation-induced gastrointestinal syndrome in mice independent of apoptosis. Science (2009) 2.11
HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol (2011) 2.10
In vivo wide-area cellular imaging by side-view endomicroscopy. Nat Methods (2010) 2.10
Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci U S A (2006) 2.09
Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res (2002) 2.09
Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood (2005) 1.98
Fluorescent nanorods and nanospheres for real-time in vivo probing of nanoparticle shape-dependent tumor penetration. Angew Chem Int Ed Engl (2011) 1.93
Micro-environmental mechanical stress controls tumor spheroid size and morphology by suppressing proliferation and inducing apoptosis in cancer cells. PLoS One (2009) 1.92
Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell (2005) 1.89
Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed? Lancet Oncol (2007) 1.89
Impaired lymphatic contraction associated with immunosuppression. Proc Natl Acad Sci U S A (2011) 1.88
Simultaneous measurement of RBC velocity, flux, hematocrit and shear rate in vascular networks. Nat Methods (2010) 1.88
A genetic Xenopus laevis tadpole model to study lymphangiogenesis. Nat Med (2005) 1.85
Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res (2010) 1.84
A nanoparticle size series for in vivo fluorescence imaging. Angew Chem Int Ed Engl (2010) 1.84
Mechanical compression drives cancer cells toward invasive phenotype. Proc Natl Acad Sci U S A (2011) 1.84
Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci U S A (2013) 1.83
Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol Cancer Ther (2008) 1.83
Engineered blood vessel networks connect to host vasculature via wrapping-and-tapping anastomosis. Blood (2011) 1.82
Differential transplantability of tumor-associated stromal cells. Cancer Res (2004) 1.78
Polycyclic aromatic hydrocarbons: environmental pollution and bioremediation. Trends Biotechnol (2002) 1.77
Imaging angiogenesis and the microenvironment. APMIS (2008) 1.77
Robust 3-D modeling of vasculature imagery using superellipsoids. IEEE Trans Med Imaging (2007) 1.76
Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res (2013) 1.73
Peritumor lymphatics induced by vascular endothelial growth factor-C exhibit abnormal function. Cancer Res (2004) 1.72
A mathematical model of murine metabolic regulation by leptin: energy balance and defense of a stable body weight. Cell Metab (2009) 1.72
Cancer imaging by optical coherence tomography: preclinical progress and clinical potential. Nat Rev Cancer (2012) 1.72
Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: mechanism of low pH-induced VEGF. J Biol Chem (2001) 1.72
Compact high-quality CdSe-CdS core-shell nanocrystals with narrow emission linewidths and suppressed blinking. Nat Mater (2013) 1.71
Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res (2011) 1.69
Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression. J Natl Cancer Inst (2013) 1.69
Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med (2012) 1.66
NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J Clin Invest (2005) 1.65
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res (2009) 1.64
Solid stress generated by spheroid growth estimated using a linear poroelasticity model. Microvasc Res (2003) 1.64
VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med (2007) 1.64
Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol (2010) 1.63
Compact biocompatible quantum dots via RAFT-mediated synthesis of imidazole-based random copolymer ligand. J Am Chem Soc (2010) 1.60
Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis. Cancer Res (2006) 1.60
Perivascular nitric oxide gradients normalize tumor vasculature. Nat Med (2008) 1.56
Scaling rules for diffusive drug delivery in tumor and normal tissues. Proc Natl Acad Sci U S A (2011) 1.54
PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment. PLoS One (2009) 1.52
TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc Natl Acad Sci U S A (2012) 1.51
Biofilms: implications in bioremediation. Trends Microbiol (2006) 1.51